As of the most recent data (June 2026), EYES shows a long-term debt of $16M. That compares with $17M in the prior-year period — down 7.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EYES's long-term debt is now $16M (was $17M) — a 7.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Second Sight Medical Products is outperforming or lagging.

Tracking EYES's long-term debt over time shows whether Second Sight Medical Products is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $17M in the prior-year period — down 7.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Second Sight Medical Products's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $16M) with ownership activity and broader fundamentals.

Second Sight Medical Products's long-term debt is $16M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.